Rheumatology

Granted to Ipsen, the breakthrough treatment reduces new, abnormal bone growth in people living with the ultra-rare bone disease.

This systematic review found 26 DMARDs in clinical development for spondyloarthritis, including psoriatic arthritis, but their target diversity was low.

Experts discuss their therapeutic approach and key agents utilized in the treatment of fibromyalgia (FM).

Common themes among patients and parents included a need to accurately assess pain and offer non-pharmacological options for pain management.

Experts discuss treatment options for fibromyalgia (FM) and how they utilize integrative care with patients.

Experts discuss which providers often diagnose fibromyalgia (FM) and how the burden of care has changed in recent years.

All 30 neuropsychiatric symptoms included were significantly higher in patients with systemic autoimmune rheumatic diseases when compared with controls.

The median central sensitization, frequency of neuropathic pain, and frequency of fibromyalgia diagnosis were higher in patients with axSpA when compared with controls.

Experts discuss common comorbidities for patients with fibromyalgia (FM).

Experts offer clinical experience on why fibromyalgia (FM) is challenging to diagnose and how they rule out other chronic pain disorders.

Pediatric rheumatologists were most likely to postpone the decision to withdraw biologic therapy when the patient and/or parents expressed a preference for continuation.

Experts offer their clinical advice on what factors, outside of clinical therapies, may mitigate symptoms of fibromyalgia (FM).

Experts discuss the common characteristics of fibromyalgia (FM) and related symptoms.

Although the benefits of telehealth are clear, it is not without its challenges. As the field of rheumatology moves into a post-pandemic world, the future of telemedicine hangs in the balance.

Patients identified areas of confusion in data presentation and suggested educational support to better engage with the information provided.

Experts discuss known risk factors of fibromyalgia (FM).

Experts discuss the pathophysiology of fibromyalgia (FM) and how it relates to other chronic pain diseases.

Experts offer their clinical experience on why fibromyalgia (FM) is often misunderstood by patients and practitioners.

Wendy Wright, DNP, Kostas Botsoglou, MD, Daniel Clauw, MD, and Benjamin Natelson, MD, present an overview of symptoms and characteristics of fibromyalgia (FM).

The risk of ischemia heart disease was significantly higher in the SLE cohort when compared with controls, with risks peaking between the 6th and 9th year post-diagnosis.

NHANES data presented at EULAR 2023 offer insight into trends in the risk of mortality over a time period beginning in 1988 and lasting through 2016.

An analysis of the ORAL Surveillance trial details the efficacy of tofacitinib relative to TNF inhibition based on history of ASCVD and baseline cardiovascular risk.

Patients in the land- and water-based exercise intervention groups demonstrated greater improvements in fatigue when compared with controls.

More than 90% of respondents reported being “somewhat likely” or “very likely” to speak with an online coach ≥2 per week or spend 1 – 2 hours per week learning about lifestyle behaviors if given the opportunity.

Data presented at EULAR 2023 details the factors that matter most to patients with gout when considering the continuation or discontinuation of urate-lowering therapy after achieving clinical remission.

A new-user, active comparator cohort study from EULAR 2023 suggests use of SGLT2 inhibitors could lower risk of recurrent gout flares in people with type 2 diabetes and gout compared to use of DPP-4 inhibitors.

A pair of studies presented at EULAR 2023 offer perspective on the potential for postpartum depression as well as symptoms of depression and anxiety during pregnancy among women with rheumatic disease.

A group of rheumatologists attending EULAR 2023 provide perspective on their concern regarding the potential threat posed by long COVID in patients with rheumatic disease.

An analysis of data from the phase 2 AURA-LV and phase 3 AURORA 1 trials provides new insight into the effects of voclosporin for the treatment of active lupus nephritis in patients with high proteinuria.

After 12 weeks of treatment, the median sUA levels of patients with gout were reduced from 8.6 mg/dL to 3.6 mg/dL in the AR882 75 mg cohort and 5.0 mg/dL in the AR882 50 mg group.